Advertisement

Alternative hosts and model animals

The severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) pandemic may have originated in bats, but how it made its way into humans is unknown. Because of its zoonotic origins, SARS-CoV-2 is unlikely to exclusively infect humans, so it would be valuable to have an animal model for drug and vaccine development. Shi et al. tested ferrets, as well as livestock and companion animals of humans, for their susceptibility to SARS-CoV-2 (see the Perspective by Lakdawala and Menachery). The authors found that SARS-CoV-2 infects the upper respiratory tracts of ferrets but is poorly transmissible between individuals. In cats, the virus replicated in the nose and throat and caused inflammatory pathology deeper in the respiratory tract, and airborne transmission did occur between pairs of cats. Dogs appeared not to support viral replication well and had low susceptibility to the virus, and pigs, chickens, and ducks were not susceptible to SARS-CoV-2.
Science, this issue p. 1016; see also p. 942

Abstract

Severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) causes the infectious disease COVID-19 (coronavirus disease 2019), which was first reported in Wuhan, China, in December 2019. Despite extensive efforts to control the disease, COVID-19 has now spread to more than 100 countries and caused a global pandemic. SARS-CoV-2 is thought to have originated in bats; however, the intermediate animal sources of the virus are unknown. In this study, we investigated the susceptibility of ferrets and animals in close contact with humans to SARS-CoV-2. We found that SARS-CoV-2 replicates poorly in dogs, pigs, chickens, and ducks, but ferrets and cats are permissive to infection. Additionally, cats are susceptible to airborne transmission. Our study provides insights into the animal models for SARS-CoV-2 and animal management for COVID-19 control.
In late December 2019, an unusual pneumonia emerged in humans in Wuhan, China, and rapidly spread internationally, raising global public health concerns. The causative pathogen was identified as a novel coronavirus (116) and named severe acute respiratory syndrome–coronavirus 2 (SARS-CoV-2) on the basis of a phylogenetic analysis of related coronaviruses by the Coronaviridae Study Group of the International Committee on Taxonomy of Viruses (17). Subsequently, the disease caused by this virus was designated coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO). Despite major efforts to control the COVID-19 outbreak, the disease is still spreading. As of 11 March 2020, SARS-CoV-2 infections have been reported in more than 100 countries, and 118,326 human cases have been confirmed, with 4292 fatalities (18). WHO has now officially declared COVID-19 a pandemic.
Although SARS-CoV-2 shares 96.2% of its identity at the nucleotide level with the coronavirus RaTG13—which was detected in horseshoe bats (Rhinolophus spp.) in Yunnan province, China, in 2013 (3)—it has not previously been detected in humans or other animals. The emerging public health crisis raises many urgent questions. Could the widely disseminated SARS-CoV-2 be transmitted to other animal species, which then become reservoirs of infection? The SARS-CoV-2 infection has a wide clinical spectrum in humans, ranging from mild infection to death, but how does the virus behave in other animals? As efforts progress toward vaccine and antiviral drug development, which animal(s) can be used to most accurately model the efficacy of such control measures in humans? To address these questions, we evaluated the susceptibility of different model laboratory animals, as well as companion and domestic animals, to SARS-CoV-2.
All experiments with infectious SARS-CoV-2 were performed in the biosafety level 4 and animal biosafety level 4 facilities in the Harbin Veterinary Research Institute (HVRI) of the Chinese Academy of Agricultural Sciences (CAAS), which was approved for such use by the Ministry of Agriculture and Rural Affairs of China. Details of the biosafety and biosecurity measures are provided in the supplementary materials (19). The protocols for animal study and animal welfare were reviewed and approved by the Committee on the Ethics of Animal Experiments of the HVRI of CAAS (approval number 2020-01-01JiPi).
Ferrets are commonly used as an animal model for viral respiratory infections in humans (2026). We therefore tested the susceptibility of ferrets to SARS-CoV-2. Two virus strains were used in this study: (i) SARS-CoV-2/F13/environment/2020/Wuhan (F13-E), isolated from an environmental sample collected in the Huanan Seafood Market in Wuhan, and (ii) SARS-CoV-2/CTan/human/2020/Wuhan (CTan-H), isolated from a human patient. Pairs of ferrets were inoculated intranasally with 105 plaque-forming units (PFU) of F13-E or CTan-H and euthanized on day 4 postinoculation (p.i.). The nasal turbinate, soft palate, tonsils, trachea, lung, heart, liver, spleen, kidneys, pancreas, small intestine, and brain from each ferret were collected for viral RNA quantification by quantitative polymerase chain reaction and virus titration in Vero E6 cells. Viral RNA (Fig. 1, A and B) and infectious virus (Fig. 1, C and D) were detected in the nasal turbinate, soft palate, and tonsils of all four ferrets inoculated with these two viruses but were not detected in any other organs tested. These results indicate that SARS-CoV-2 can replicate in the upper respiratory tract of ferrets, but its replication in other organs is undetectable.
Fig. 1 Replication of SARS-CoV-2 in ferrets.
Viral RNA in organs or tissues of ferrets inoculated with (A) F13-E virus strain or (B) CTan-H strain. Viral titers in organs or tissues of ferrets inoculated with F13-E (C) and CTan-H (D). The viral RNA–negative organs indicted in (A) and (B) were also negative for virus titration [indicated as “Others” in (C) and (D)]. Viral RNA (E and F) and viral titer (G and H) in nasal washes of ferrets inoculated with F13-E [(E) and (G)] and CTan-H [(F) and (H)]. Antibodies against SARS-CoV-2 tested by ELISA (I and J) and neutralization assay (K and L) with sera derived from ferrets inoculated with F13-E [(I) and (K)] and CTan-H [(J) and (L)]. Each color bar represents the value from an individual animal. The gray bars in (I) to (L) indicate the antibody values of sera collected from each animal before inoculation. Asterisks denote animals that were euthanized on day 13 p.i.; the other four animals were euthanized on day 20 p.i. The dashed lines in (I) and (L) show the cutoff value for seroconversion, and the dashed lines in the other panels indicate the lower limit of detection. OD450, optical density measured at 450 nm; NT antibody, neutralizing antibody.
To investigate the replication dynamics of these virus strains in ferrets, groups of three animals were inoculated intranasally with 105 PFU of F13-E or CTan-H, and each ferret was then placed in a separate cage within an isolator. Nasal washes and rectal swabs were collected on days 2, 4, 6, 8, and 10 p.i. from the ferrets for viral RNA detection and virus titration. Body temperatures and signs of disease were monitored for 2 weeks. Viral RNA was detected in the nasal washes on days 2, 4, 6, and 8 p.i. in all six ferrets inoculated with the two strains (Fig. 1, E and F). Viral RNA was also detected in some of the rectal swabs of the virus-inoculated ferrets, although the copy numbers were notably lower than those in the nasal washes of these ferrets (fig. S1, A and C). Infectious virus was detected from the nasal washes of all ferrets (Fig. 1, G and H) but not from the rectal swabs of any ferrets (fig. S1, B and D).
One ferret from each virus-inoculated group developed fever and loss of appetite on days 10 (CTan-H–inoculated) and 12 p.i. (F13-E–inoculated), respectively. To investigate whether these symptoms were caused by virus replication in the lower respiratory tract, we euthanized the two ferrets on day 13 p.i. and collected their organs for viral RNA detection. However, viral RNA was not detected in any other tissues or organs of either ferret, except for a low copy number (105.4 copies/g) in the turbinate of the ferret inoculated with CTan-H (fig. S2). Pathological studies revealed severe lymphoplasmacytic perivasculitis and vasculitis; increased numbers of type II pneumocytes, macrophages, and neutrophils in the alveolar septa and alveolar lumen; and mild peribronchitis in the lungs of the two ferrets euthanized on day 13 p.i. (fig. S3). Antibodies against SARS-CoV-2 were detected in all ferrets by an enzyme-linked immunosorbent assay (ELISA) and a neutralization assay, although the antibody titers of the two ferrets that were euthanized on day 13 p.i. were notably lower than those of the ferrets euthanized on day 20 p.i. (Fig. 1, I to L).
A virus attachment assay indicated that SARS-CoV-2 could attach to bronchiolar epithelial cells (fig. S4A) and some type II pneumocytes (fig. S4B) in ferret lungs. To further investigate whether SARS-CoV-2 replicates in the lungs of ferrets, we intratracheally inoculated eight ferrets with 105 PFU of CTan-H and euthanized two animals each on days 2, 4, 8, and 14 p.i. to look for viral RNA in the tissues and organs. Viral RNA was detected only in the nasal turbinate and soft palate of one ferret in each pair euthanized on days 2 and 4 p.i.; was detected in the soft palate of one ferret and in the nasal turbinate, soft palate, tonsils, and trachea of the other ferret euthanized on day 8 p.i.; and was not detected in either of the two ferrets euthanized on day 14 p.i. (fig. S5). These results indicate that SARS-CoV-2 can replicate in the upper respiratory tract of ferrets for up to 8 days without causing severe disease or death.
Cats and dogs are in close contact with humans; therefore, it is important to understand their susceptibility to SARS-CoV-2. We first investigated the replication of SARS-CoV-2 in cats. Seven subadult cats (aged 6 to 9 months, outbred domestic cats) were intranasally inoculated with 105 PFU of CTan-H. Two animals were scheduled to be euthanized on days 3 and 6 p.i., respectively, to evaluate viral replication in their organs. Three subadult cats were placed in separate cages within an isolator. To monitor respiratory droplet transmission, an uninfected cat was placed in a cage adjacent to each of the infected cats. The aggressive behavior of the subadult cats made it difficult to perform regular nasal wash collection. To avoid possible injury, we only collected feces from these cats and checked for viral RNA in their organs after euthanasia.
Viral RNA was detected in the nasal turbinate of one animal, as well as in the soft palates, tonsils, tracheas, lungs, and small intestines of both animals euthanized on day 3 p.i. (Fig. 2A). In the animals euthanized on day 6 p.i., viral RNA was detected in the nasal turbinates, soft palates, and tonsils of both animals; in the trachea of one animal; and in the small intestine of the other. However, viral RNA was not detected in any lung samples from either of these animals (Fig. 2C). Infectious virus was detected in the viral RNA–positive nasal turbinates, soft palates, tonsils, tracheas, and lungs of these cats but was not recovered from the viral RNA–positive small intestines (Fig. 2, B and D)
Fig. 2 Replication of SARS-CoV-2 in cats.
Subadult cats and juvenile cats inoculated with CTan-H virus were euthanized on days 3 and 6 p.i., and their organs were collected for viral RNA detection and virus titration. (A) Viral RNA and (B) viral titers of subadult cats on day 3 p.i. (C) Viral RNA and (D) viral titers of subadult cats on day 6 p.i. (E) Viral RNA and (F) viral titers of juvenile cats on day 3 p.i. The values of red bars in (E) and (F) are from the cat that died on this day. (G) Viral RNA and (H) viral titers of juvenile cats on day 6 p.i. “Others” represents viral-negative organs, including the brain, heart, submaxillary lymph nodes, kidneys, spleen, liver, and pancreas. Each color bar represents the value from an individual animal. The dashed lines indicate the lower limit of detection.
In the transmission study, viral RNA was detected in the feces of two virus-inoculated subadult cats on day 3 p.i. and in all three virus-inoculated subadult cats on day 5 p.i. (Fig. 3A). Viral RNA was detected in the feces of one exposed cat on day 3 p.i. (Fig. 3A). The pair of subadult cats with viral RNA–positive feces was euthanized on day 11 p.i. Viral RNA was detected in the soft palate and tonsils of the virus-inoculated animal and in the nasal turbinate, soft palate, tonsils, and trachea of the exposed animal (Fig. 3B), indicating that respiratory droplet transmission had occurred. We euthanized the other pairs on day 12 p.i. Viral RNA was detected in the tonsils of one virus-inoculated subadult cat and in the nasal turbinate, soft palate, tonsils, and trachea of the other virus-inoculated subadult cat but was not detected in any organs or tissues of the two exposed subadult cats (Fig. 3B). Antibodies against SARS-CoV-2 were detected in all three virus-inoculated subadult cats and one exposed cat via an ELISA and neutralization assay (Fig. 3, C and D).
Fig. 3 Transmission of SARS-CoV-2 in cats.
Transmission of the CTan-H virus strain was evaluated in subadult cats (A to D) and juvenile cats (E to G). (A) Viral RNA in the feces of virus-inoculated or virus-exposed subadult cats. (B) Viral RNA in tissues or organs of inoculated or exposed subadult cats euthanized on day 11 p.i. (pair 1, red bars) or day 12 p.i. (pairs 2 and 3). Antibodies against SARS-CoV-2 in these euthanized subadult cats were detected by ELISA (C) and neutralization assay (D). (E) Viral RNA in nasal washes of juvenile cats. Sera from juvenile cats were collected on day 20 p.i., except for sera from one virus-inoculated animal that died on day 13 p.i. Antibody values for this cat (indicated by asterisks) were detected from sera collected on day 10 p.i.; antibodies against SARS-CoV-2 were detected by ELISA (F) and neutralization assay (G). Each color bar represents the value from an individual animal. The horizontal dashed lines in (C) and (F) show the cutoff value for seroconversion, and the horizontal dashed lines in the other panels indicate the lower limit of detection.
We repeated the replication and transmission studies in juvenile cats (aged 70 to 100 days) (Figs. 2, E to H, and 3, E to G, and fig. S6). Histopathologic studies performed on samples from the virus-inoculated juvenile cats that died or were euthanized on day 3 p.i. revealed massive lesions in the nasal and tracheal mucosa epitheliums and lungs (fig. S7). These results indicate that SARS-CoV-2 can replicate efficiently in cats and that younger cats are more vulnerable than older ones. Notably, our findings also reveal that the virus is transmissible between cats via the airborne route.
We next investigated the replication and transmission of SARS-CoV-2 in dogs. Five 3-month-old beagles were intranasally inoculated with 105 PFU of CTan-H and housed with two uninoculated beagles in a room. Oropharyngeal and rectal swabs from each beagle were collected on days 2, 4, 6, 8, 10, 12, and 14 p.i. for viral RNA detection and virus titration in Vero E6 cells. Viral RNA was detected in the rectal swabs of two virus-inoculated dogs on day 2 p.i. and in the rectal swab of one such dog on day 6 p.i. (Table 1). One dog that was positive for viral RNA by rectal swab on day 2 p.i. was euthanized on day 4 p.i., but viral RNA was not detected in any organs or tissues collected from this animal (fig. S8). Additionally, infectious virus was not detected in any swabs collected from any of these dogs. Sera were collected from all dogs on day 14 p.i. for antibody detection by an ELISA. Two virus-inoculated dogs seroconverted; the other two virus-inoculated dogs and the two contact-exposed dogs were all seronegative for SARS-CoV-2 (Table 1 and fig. S9). These results indicate that dogs have low susceptibility to SARS-CoV-2.
Animal Treatment Viral RNA detection in animals inoculated with SARS-CoV-2 isolate CTan-H;
positive cases/total (copies, log10)
Seroconversion;
positive
cases/total†
Oropharyngeal swab Rectal swab
Day 2 p.i. Day 4 p.i. Day 6 p.i. Other time
points
Day 2 p.i. Day 4 p.i. Day 6 p.i. Other time
points
Dog* Inoculated 0/5 0/5 0/4 0/4 2/5 (6.5, 5.4) 0/5 1/4 (4.2) 0/4 2/4
Contact 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2
Pig Inoculated 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5
Contact 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3
Chicken Inoculated 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5
Contact 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3
Duck Inoculated 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5 0/5
Contact 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3 0/3
Table 1 Susceptibility of dogs, pigs, chickens, and ducks to SARS-CoV-2.
Animals were intranasally inoculated with 105 PFU (dogs and pigs) or 104.5 PFU (chickens and ducks) of the CTan-H virus strain. Two (dogs) or three (pigs, chickens, and ducks) uninfected animals were housed in the same room with their infected counterparts to monitor transmission of the virus. Oropharyngeal and rectal swabs from all animals were collected on the indicated days postinoculation (p.i.) for viral RNA detection. The “Other time points” category includes days 8, 10, 12, and 14 p.i.

*One virus-inoculated beagle was euthanized on day 4 p.i., but viral RNA was not detected in any of its collected organs, which included lung, trachea, nasal turbinate, soft palate, brain, heart, tonsils, kidneys, spleen, liver, pancreas, and small intestine (fig. S6).

†Sera were collected from all animals on day 14 p.i., and antibodies against SARS-CoV-2 were detected by using a double-antigen sandwich ELISA kit (ProtTech, Luoyang, China).

We also investigated the susceptibility of pigs, chickens, and ducks to SARS-CoV-2 by using the same strategy as that used to assess dogs. However, viral RNA was not detected in any swabs collected from these virus-inoculated animals or from naïve contact animals (Table 1). In addition, all of these animals were seronegative for SARS-CoV-2 when tested by ELISA with sera collected on day 14 p.i. (Table 1). These results indicate that pigs, chickens, and ducks are not susceptible to SARS-CoV-2.
In summary, we found that ferrets and cats are highly susceptible to SARS-CoV-2; dogs have low susceptibility; and pigs, chickens, and ducks are not susceptible to the virus. Unlike influenza viruses and the other SARS-coronavirus known to infect humans (SARS-CoV-1), which replicate in both the upper and lower respiratory tract of ferrets (20, 2224, 26, 27), SARS-CoV-2 replicates only in the nasal turbinate, soft palate, and tonsils of ferrets. SARS-CoV-2 may also replicate in the digestive tract, as viral RNA was detected in the rectal swabs of the virus-infected ferrets, but virus was not detected in lung lobes, even after the ferrets were intratracheally inoculated with the virus. It remains unclear whether the virus causes more severe disease in male ferrets than in female ferrets, as has been observed among humans (13, 28).
Several studies have reported that SARS-CoV-2 uses angiotensin-converting enzyme 2 (ACE2) as its receptor to enter cells (3, 2931). ACE2 is mainly expressed in type II pneumocytes and serous epithelial cells of tracheo-bronchial submucosal glands in ferrets (25). Ferrets and cats differ by only two amino acids in the SARS-CoV-2 spike-contacting regions of ACE2 (table S1); therefore, the underlying mechanism that prevents the replication of SARS-CoV-2 in the lower respiratory tract of ferrets remains to be investigated. The fact that SARS-CoV-2 replicates efficiently in the upper respiratory tract of ferrets makes them a candidate animal model for evaluating the efficacy of antiviral drugs or vaccines against COVID-19.
The cats we used in this study were outbred and were susceptible to SARS-CoV-2, which replicated efficiently and was transmissible to naïve cats. Cats in Wuhan have been reported to be seropositive for SARS-CoV-2 (32). Surveillance for SARS-CoV-2 in cats should be considered as an adjunct to elimination of COVID-19 in humans.

Acknowledgments

We thank S. Watson for editing the manuscript. Funding: This work was supported by the National Key R&D Program of China (2020YFC0846500, 2018YFC1200601, and 2016YFD0500301). Author contributions: J.S., Z.W., G.Z., H.Y., C.W., B.H., R.L., X.H., L.S., Z.S., Y.Z., P.L., L.L., P.C., J.W., X.Z., and Y.G. performed experiments; J.S., Z.W., G.Z., H.Y., C.W., W.T., G.W., H.C., and Z.B. analyzed data; and Z.B. and H.C. designed the study and wrote the manuscript. Competing interests: None of the authors have any competing interests. Data and materials availability: All data are available in the manuscript or the supplementary materials. Sequences of the viruses used in this study have been deposited in GISAID previously with the accession numbers EPI_ISL_402119 and EPI_ISL_408514. Two strains of 2019 novel coronavirus (CTan-H and F13-E) were obtained from the China CDC under a material transfer agreement that allows use only in P3+ or P4 facilities, prevents live virus sharing, and prevents commercial use. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.

Supplementary Material

Summary

Materials and Methods
Supplementary Text
Figs. S1 to S10
Table S1
References and Notes (3335)
MDAR Reproducibility Checklist

Resources

File (abb7015_shi_mdar_reproducibility_checklist.pdf)
File (abb7015_shi_sm.pdf)

References and Notes

1
L. Zou, F. Ruan, M. Huang, L. Liang, H. Huang, Z. Hong, J. Yu, M. Kang, Y. Song, J. Xia, Q. Guo, T. Song, J. He, H.-L. Yen, M. Peiris, J. Wu, SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N. Engl. J. Med. 382, 1177–1179 (2020).
2
N. Zhu, D. Zhang, W. Wang, X. Li, B. Yang, J. Song, X. Zhao, B. Huang, W. Shi, R. Lu, P. Niu, F. Zhan, X. Ma, D. Wang, W. Xu, G. Wu, G. F. Gao, W. Tan, China Novel Coronavirus Investigating and Research Team, A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 382, 727–733 (2020).
3
P. Zhou, X.-L. Yang, X.-G. Wang, B. Hu, L. Zhang, W. Zhang, H.-R. Si, Y. Zhu, B. Li, C.-L. Huang, H.-D. Chen, J. Chen, Y. Luo, H. Guo, R.-D. Jiang, M.-Q. Liu, Y. Chen, X.-R. Shen, X. Wang, X.-S. Zheng, K. Zhao, Q.-J. Chen, F. Deng, L.-L. Liu, B. Yan, F.-X. Zhan, Y.-Y. Wang, G.-F. Xiao, Z.-L. Shi, A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579, 270–273 (2020).
4
F. Wu, S. Zhao, B. Yu, Y.-M. Chen, W. Wang, Z.-G. Song, Y. Hu, Z.-W. Tao, J.-H. Tian, Y.-Y. Pei, M.-L. Yuan, Y.-L. Zhang, F.-H. Dai, Y. Liu, Q.-M. Wang, J.-J. Zheng, L. Xu, E. C. Holmes, Y.-Z. Zhang, A new coronavirus associated with human respiratory disease in China. Nature 579, 265–269 (2020).
5
A. Wu, Y. Peng, B. Huang, X. Ding, X. Wang, P. Niu, J. Meng, Z. Zhu, Z. Zhang, J. Wang, J. Sheng, L. Quan, Z. Xia, W. Tan, G. Cheng, T. Jiang, Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. Cell Host Microbe 27, 325–328 (2020).
6
C. Wang, P. W. Horby, F. G. Hayden, G. F. Gao, A novel coronavirus outbreak of global health concern. Lancet 395, 470–473 (2020).
7
Y. Pan, D. Zhang, P. Yang, L. L. M. Poon, Q. Wang, Viral load of SARS-CoV-2 in clinical samples. Lancet Infect. Dis. 20, 411–412 (2020).
8
X. Pan, D. Chen, Y. Xia, X. Wu, T. Li, X. Ou, L. Zhou, J. Liu, Asymptomatic cases in a family cluster with SARS-CoV-2 infection. Lancet Infect. Dis. 20, 410–411 (2020).
9
R. Lu, X. Zhao, J. Li, P. Niu, B. Yang, H. Wu, W. Wang, H. Song, B. Huang, N. Zhu, Y. Bi, X. Ma, F. Zhan, L. Wang, T. Hu, H. Zhou, Z. Hu, W. Zhou, L. Zhao, J. Chen, Y. Meng, J. Wang, Y. Lin, J. Yuan, Z. Xie, J. Ma, W. J. Liu, D. Wang, W. Xu, E. C. Holmes, G. F. Gao, G. Wu, W. Chen, W. Shi, W. Tan, Genomic characterisation and epidemiology of 2019 novel coronavirus: Implications for virus origins and receptor binding. Lancet 395, 565–574 (2020).
10
P. Liu, X. Z. Tan, 2019 Novel Coronavirus (2019-nCoV) Pneumonia. Radiology 295, 19 (2020).
11
Q. Li, X. Guan, P. Wu, X. Wang, L. Zhou, Y. Tong, R. Ren, K. S. M. Leung, E. H. Y. Lau, J. Y. Wong, X. Xing, N. Xiang, Y. Wu, C. Li, Q. Chen, D. Li, T. Liu, J. Zhao, M. Liu, W. Tu, C. Chen, L. Jin, R. Yang, Q. Wang, S. Zhou, R. Wang, H. Liu, Y. Luo, Y. Liu, G. Shao, H. Li, Z. Tao, Y. Yang, Z. Deng, B. Liu, Z. Ma, Y. Zhang, G. Shi, T. T. Y. Lam, J. T. Wu, G. F. Gao, B. J. Cowling, B. Yang, G. M. Leung, Z. Feng, Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N. Engl. J. Med. 382, 1199–1207 (2020).
12
C. Huang, Y. Wang, X. Li, L. Ren, J. Zhao, Y. Hu, L. Zhang, G. Fan, J. Xu, X. Gu, Z. Cheng, T. Yu, J. Xia, Y. Wei, W. Wu, X. Xie, W. Yin, H. Li, M. Liu, Y. Xiao, H. Gao, L. Guo, J. Xie, G. Wang, R. Jiang, Z. Gao, Q. Jin, J. Wang, B. Cao, Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395, 497–506 (2020).
13
W. J. Guan, Z. Y. Ni, Y. Hu, W. H. Liang, C. Q. Ou, J. X. He, L. Liu, H. Shan, C. L. Lei, D. S. C. Hui, B. Du, L. J. Li, G. Zeng, K. Y. Yuen, R. C. Chen, C. L. Tang, T. Wang, P. Y. Chen, J. Xiang, S. Y. Li, J. L. Wang, Z. J. Liang, Y. X. Peng, L. Wei, Y. Liu, Y. H. Hu, P. Peng, J. M. Wang, J. Y. Liu, Z. Chen, G. Li, Z. J. Zheng, S. Q. Qiu, J. Luo, C. J. Ye, S. Y. Zhu, N. S. Zhong, China Medical Treatment Expert Group for Covid-19, Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 10.1056/NEJMoa2002032 (2020). 10.1056/NEJMoa2002032
14
N. Chen, M. Zhou, X. Dong, J. Qu, F. Gong, Y. Han, Y. Qiu, J. Wang, Y. Liu, Y. Wei, J. Xia, T. Yu, X. Zhang, L. Zhang, Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet 395, 507–513 (2020).
15
J. F. Chan, S. Yuan, K.-H. Kok, K. K.-W. To, H. Chu, J. Yang, F. Xing, J. Liu, C. C.-Y. Yip, R. W.-S. Poon, H.-W. Tsoi, S. K.-F. Lo, K.-H. Chan, V. K.-M. Poon, W.-M. Chan, J. D. Ip, J.-P. Cai, V. C.-C. Cheng, H. Chen, C. K.-M. Hui, K.-Y. Yuen, A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: A study of a family cluster. Lancet 395, 514–523 (2020).
16
J. F. Chan, K.-H. Kok, Z. Zhu, H. Chu, K. K.-W. To, S. Yuan, K.-Y. Yuen, Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg. Microbes Infect. 9, 221–236 (2020).
17
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, The species Severe acute respiratory syndrome-related coronavirus: Classifying 2019-nCoV and naming it SARS-CoV-2. Nat. Microbiol. 5, 536–544 (2020).
18
World Health Organization (WHO), “Coronavirus disease 2019 (COVID-19): Situation Report – 51” (WHO, 2020); www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_4.
19
See supplementary materials.
20
J. Shi, G. Deng, H. Kong, C. Gu, S. Ma, X. Yin, X. Zeng, P. Cui, Y. Chen, H. Yang, X. Wan, X. Wang, L. Liu, P. Chen, Y. Jiang, J. Liu, Y. Guan, Y. Suzuki, M. Li, Z. Qu, L. Guan, J. Zang, W. Gu, S. Han, Y. Song, Y. Hu, Z. Wang, L. Gu, W. Yang, L. Liang, H. Bao, G. Tian, Y. Li, C. Qiao, L. Jiang, C. Li, Z. Bu, H. Chen, H7N9 virulent mutants detected in chickens in China pose an increased threat to humans. Cell Res. 27, 1409–1421 (2017).
21
K. J. Stittelaar, L. de Waal, G. van Amerongen, E. J. Veldhuis Kroeze, P. L. Fraaij, C. A. van Baalen, J. J. van Kampen, E. van der Vries, A. D. Osterhaus, R. L. de Swart, Ferrets as a Novel Animal Model for Studying Human Respiratory Syncytial Virus Infections in Immunocompetent and Immunocompromised Hosts. Viruses 8, 168 (2016).
22
Q. Zhang, J. Shi, G. Deng, J. Guo, X. Zeng, X. He, H. Kong, C. Gu, X. Li, J. Liu, G. Wang, Y. Chen, L. Liu, L. Liang, Y. Li, J. Fan, J. Wang, W. Li, L. Guan, Q. Li, H. Yang, P. Chen, L. Jiang, Y. Guan, X. Xin, Y. Jiang, G. Tian, X. Wang, C. Qiao, C. Li, Z. Bu, H. Chen, H7N9 influenza viruses are transmissible in ferrets by respiratory droplet. Science 341, 410–414 (2013).
23
M. Imai, T. Watanabe, M. Hatta, S. C. Das, M. Ozawa, K. Shinya, G. Zhong, A. Hanson, H. Katsura, S. Watanabe, C. Li, E. Kawakami, S. Yamada, M. Kiso, Y. Suzuki, E. A. Maher, G. Neumann, Y. Kawaoka, Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature 486, 420–428 (2012).
24
S. Herfst, E. J. A. Schrauwen, M. Linster, S. Chutinimitkul, E. de Wit, V. J. Munster, E. M. Sorrell, T. M. Bestebroer, D. F. Burke, D. J. Smith, G. F. Rimmelzwaan, A. D. M. E. Osterhaus, R. A. M. Fouchier, Airborne transmission of influenza A/H5N1 virus between ferrets. Science 336, 1534–1541 (2012).
25
J. M. van den Brand, B. L. Haagmans, L. Leijten, D. van Riel, B. E. E. Martina, A. D. M. E. Osterhaus, T. Kuiken, Pathology of experimental SARS coronavirus infection in cats and ferrets. Vet. Pathol. 45, 551–562 (2008).
26
B. E. Martina, B. L. Haagmans, T. Kuiken, R. A. M. Fouchier, G. F. Rimmelzwaan, G. Van Amerongen, J. S. M. Peiris, W. Lim, A. D. M. E. Osterhaus, Virology: SARS virus infection of cats and ferrets. Nature 425, 915 (2003).
27
Y. K. Chu, G. D. Ali, F. Jia, Q. Li, D. Kelvin, R. C. Couch, K. S. Harrod, J. A. Hutt, C. Cameron, S. R. Weiss, C. B. Jonsson, The SARS-CoV ferret model in an infection-challenge study. Virology 374, 151–163 (2008).
28
Novel Coronavirus Pneumonia Emergency Response Epidemiology Team, The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China. Zhonghua Liu Xing Bing Xue Za Zhi 41, 145–151 (2020) [in Chinese].
29
R. Yan, Y. Zhang, Y. Li, L. Xia, Y. Guo, Q. Zhou, Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444–1448 (2020).
30
M. Letko, A. Marzi, V. Munster, Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. Nat. Microbiol. 5, 562–569 (2020).
31
The Cell Editorial Team, Embracing the Landscape of Therapeutics. Cell 181, 1–3 (2020).
32
Q. Zhang, H. Zhang, K. Huang, Y. Yang, X. Hui, J. Gao, X. He, C. Li, W. Gong, Y. Zhang, C. Peng, X. Gao, H. Chen, Z. Zou, Z. Shi, M. Jin, SARS-CoV-2 neutralizing serum antibodies in cats: A serological investigation. bioRxiv (2020). https://doi.org/10.1101/2020.04.01.021196.
33
H. Yang, Y. Chen, C. Qiao, X. He, H. Zhou, Y. Sun, H. Yin, S. Meng, L. Liu, Q. Zhang, H. Kong, C. Gu, C. Li, Z. Bu, Y. Kawaoka, H. Chen, Prevalence, genetics, and transmissibility in ferrets of Eurasian avian-like H1N1 swine influenza viruses. Proc. Natl. Acad. Sci. U.S.A. 113, 392–397 (2016).
34
X. Li, J. Shi, J. Guo, G. Deng, Q. Zhang, J. Wang, X. He, K. Wang, J. Chen, Y. Li, J. Fan, H. Kong, C. Gu, Y. Guan, Y. Suzuki, Y. Kawaoka, L. Liu, Y. Jiang, G. Tian, Y. Li, Z. Bu, H. Chen, Genetics, receptor binding property, and transmissibility in mammals of naturally isolated H9N2 Avian Influenza viruses. PLOS Pathog. 10, e1004508 (2014).
35
D. van Riel, V. J. Munster, E. de Wit, G. F. Rimmelzwaan, R. A. M. Fouchier, A. D. M. E. Osterhaus, T. Kuiken, H5N1 Virus Attachment to Lower Respiratory Tract. Science 312, 399 (2006).

(0)eLetters

eLetters is a forum for ongoing peer review. eLetters are not edited, proofread, or indexed, but they are screened. eLetters should provide substantive and scholarly commentary on the article. Embedded figures cannot be submitted, and we discourage the use of figures within eLetters in general. If a figure is essential, please include a link to the figure within the text of the eLetter. Please read our Terms of Service before submitting an eLetter.

Log In to Submit a Response

No eLetters have been published for this article yet.

Information & Authors

Information

Published In

Science
Volume 368 | Issue 6494
29 May 2020

Article versions

You are viewing the most recent version of this article.

Submission history

Received: 12 March 2020
Accepted: 7 April 2020
Published in print: 29 May 2020

Permissions

Request permissions for this article.

Acknowledgments

We thank S. Watson for editing the manuscript. Funding: This work was supported by the National Key R&D Program of China (2020YFC0846500, 2018YFC1200601, and 2016YFD0500301). Author contributions: J.S., Z.W., G.Z., H.Y., C.W., B.H., R.L., X.H., L.S., Z.S., Y.Z., P.L., L.L., P.C., J.W., X.Z., and Y.G. performed experiments; J.S., Z.W., G.Z., H.Y., C.W., W.T., G.W., H.C., and Z.B. analyzed data; and Z.B. and H.C. designed the study and wrote the manuscript. Competing interests: None of the authors have any competing interests. Data and materials availability: All data are available in the manuscript or the supplementary materials. Sequences of the viruses used in this study have been deposited in GISAID previously with the accession numbers EPI_ISL_402119 and EPI_ISL_408514. Two strains of 2019 novel coronavirus (CTan-H and F13-E) were obtained from the China CDC under a material transfer agreement that allows use only in P3+ or P4 facilities, prevents live virus sharing, and prevents commercial use. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.

Authors

Affiliations

State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, People’s Republic of China.
State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, People’s Republic of China.
State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, People’s Republic of China.
State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, People’s Republic of China.
State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, People’s Republic of China.
National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, People’s Republic of China.
Renqiang Liu
State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, People’s Republic of China.
Xijun He
National High Containment Laboratory for Animal Diseases Control and Prevention, Harbin 150069, People’s Republic of China.
Lei Shuai
State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, People’s Republic of China.
Ziruo Sun
State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, People’s Republic of China.
Yubo Zhao
State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, People’s Republic of China.
National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, People’s Republic of China.
Libin Liang
State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, People’s Republic of China.
Pengfei Cui
State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, People’s Republic of China.
Jinliang Wang
State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, People’s Republic of China.
National High Containment Laboratory for Animal Diseases Control and Prevention, Harbin 150069, People’s Republic of China.
Yuntao Guan
National High Containment Laboratory for Animal Diseases Control and Prevention, Harbin 150069, People’s Republic of China.
National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, People’s Republic of China.
National Institute for Viral Disease Control and Prevention, China CDC, Beijing 102206, People’s Republic of China.
State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, People’s Republic of China.
State Key Laboratory of Veterinary Biotechnology, Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150069, People’s Republic of China.
National High Containment Laboratory for Animal Diseases Control and Prevention, Harbin 150069, People’s Republic of China.

Funding Information

The National Key Research and Development Program of China: 2018YFC1200601
The National Key Research and Development Program of China: 2020YFC0846500
The National Key Research and Development Program of China: 2016YFD0500301

Notes

*
These authors contributed equally to this work.
Corresponding author. Email: [email protected] (Z.B.); [email protected] (H.C.); [email protected] (G.W.)

Metrics & Citations

Metrics

Article Usage

Altmetrics

Citations

Cite as

Export citation

Select the format you want to export the citation of this publication.

Cited by

  1. Diabetes and the Outbreak of Coronavirus Disease (COVID-19): A Critical Review, Gene, Cell and Tissue, In Press, In Press, (2023).https://doi.org/10.5812/gct-129811
    Crossref
  2. Identification of Cell Types and Transcriptome Landscapes of Porcine Epidemic Diarrhea Virus–Infected Porcine Small Intestine Using Single-Cell RNA Sequencing, The Journal of Immunology, 210, 3, (271-282), (2023).https://doi.org/10.4049/jimmunol.2101216
    Crossref
  3. Human ELISA Detects anti-SARS-CoV-2 Antibodies in Cats: Seroprevalence and Risk Factors for Virus Spread in Domestic and Stray Cats in Bulgaria, Veterinary Sciences, 10, 1, (42), (2023).https://doi.org/10.3390/vetsci10010042
    Crossref
  4. Extracellular Vesicle-Based SARS-CoV-2 Vaccine, Vaccines, 11, 3, (539), (2023).https://doi.org/10.3390/vaccines11030539
    Crossref
  5. Stability of SARS-CoV-2 in Biological Fluids of Animals, Viruses, 15, 3, (761), (2023).https://doi.org/10.3390/v15030761
    Crossref
  6. Host Response of Syrian Hamster to SARS-CoV-2 Infection including Differences with Humans and between Sexes, Viruses, 15, 2, (428), (2023).https://doi.org/10.3390/v15020428
    Crossref
  7. Detection and Molecular Characterization of the SARS-CoV-2 Delta Variant and the Specific Immune Response in Companion Animals in Switzerland, Viruses, 15, 1, (245), (2023).https://doi.org/10.3390/v15010245
    Crossref
  8. SARS-CoV-2 Affects Both Humans and Animals: What Is the Potential Transmission Risk? A Literature Review, Microorganisms, 11, 2, (514), (2023).https://doi.org/10.3390/microorganisms11020514
    Crossref
  9. COVID-19 Biogenesis and Intracellular Transport, International Journal of Molecular Sciences, 24, 5, (4523), (2023).https://doi.org/10.3390/ijms24054523
    Crossref
  10. Induced Pluripotent Stem Cell-Derived Organoids: Their Implication in COVID-19 Modeling, International Journal of Molecular Sciences, 24, 4, (3459), (2023).https://doi.org/10.3390/ijms24043459
    Crossref
  11. See more
Loading...

View Options

View options

PDF format

Download this article as a PDF file

Download PDF

Check Access

Log in to view the full text

AAAS ID LOGIN

AAAS login provides access to Science for AAAS Members, and access to other journals in the Science family to users who have purchased individual subscriptions.

Log in via OpenAthens.
Log in via Shibboleth.

More options

Register for free to read this article

As a service to the community, this article is available for free. Login or register for free to read this article.

Purchase this issue in print

Buy a single issue of Science for just $15 USD.

Media

Figures

Multimedia

Tables

Share

Share

Share article link

Share on social media